Hans Lee, MD

In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape.

Drs Paul Richardson and Hans Lee discuss the evolving and often complex decisions around sequencing BCMA-directed therapies in multiple myeloma.

Drs Paul Richardson and Hans Lee address real-world strategies for managing cytokine release syndrome and how these considerations intersect with evolving treatment sequencing in multiple myeloma.

Hans Lee, MD, discusses the role of the CoMMit consortium as a collaborative forum shaping the future of multiple myeloma research.

Drs Paul Richardson and Hans Lee compare the three currently available BCMA-directed bispecific antibodies and discuss how differences in administration, logistics, and emerging data influence treatment selection in relapsed or refractory multiple myeloma.

Drs Paul Richardson and Hans Lee focus on practical infection mitigation strategies for patients receiving BCMA-directed bispecific antibodies, with particular emphasis on the proactive use of intravenous immunoglobulin.

Drs Paul Richardson and Hans Lee focus on the safety profile of linvoseltamab and how its clinical features translate into real-world and community-based practice.

Drs Paul Richardson and Hans Lee walk through the pivotal LINKER-MM1 trial that supported the July 2025 approval of linvoseltamab for patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy.

Exploring the complexities of treating refractory myeloma patients, highlighting the significance of BCMA as a therapeutic target and innovative treatment options.

Explore the latest advancements in treating relapsed and refractory myeloma, including innovative therapies and their real-world applications.

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.